Study on the Association Between Economic Burden of Cancer Treatment and Social Health Inequality

Jingrui Zhu

doi:10.62051/ijphmr.v5n1.03

Authors

Jingrui Zhu

DOI:

https://doi.org/10.62051/ijphmr.v5n1.03

Keywords:

Cancer treatment, Economic burden, Social health inequality, Medical resource allocation, Health insurance system

Abstract

This study investigates the correlation between cancer treatment costs and social health inequality. Through integrated analysis of hospital records and survey data, combined with regression modeling and correlation analysis, we demonstrate that socioeconomic disparities significantly influence treatment affordability. Economically disadvantaged populations face higher financial burdens, while educational limitations hinder patients' ability to make informed treatment decisions. Geographically, disparities in healthcare resources and insurance coverage between urban-rural and regional areas disproportionately burden patients in rural and economically underdeveloped regions. These findings provide critical insights for reducing cancer treatment costs and advancing social health equity.

References

[1] Li Tao; Chai Peipei; Zhang Yuhui; Wan Quan; Zhai Tiemin; Guo Feng; Li Yan; Wang Rongrong; Chen Chunmei; Liu Guoxiang. Analysis of Cancer Treatment Cost Accounting and Financing Burden in China [J]. Health Economics Research, 2021, 38(7):17-20.

[2] Jie Rong, Luo Ruijun, Li Ying, Chen Wenlin, Zhang Xiaoyang. A Qualitative Study on the Experience of Moderate to Severe Immune-Related Adverse Reactions in Immunotherapy for Malignant Tumor Patients [J]. Nursing Research, 2023, 37(11):2055-2060.

[3] Zhao Siqi; Cui Kai; Ge Xiaoyan; Ma Honglin. Analysis of Hospitalization Costs and Influencing Factors of Five Types of Cancer Patients in Jinzhou City [J]. China Health Statistics, 2023, 40(2):252-254.

[4] Zhang Fengming; Qiao Nan; Liu Huilong. Avoiding the Economic Toxicity of Treatment for Critically Ill Cancer Patients with Advanced Disease through Palliative Care [J]. Medical and Philosophy, 2023, 44(14):16-19.

[5] Ding Ying; Wang Xuanhui; Gong Chunbo. Cost-effectiveness analysis of the first-line treatment of advanced or unresectable biliary malignancies with Pavilizumab combined chemotherapy [J]. China Pharmacy, 2023, 34(23):2891-2895.

[6] Jiang Hua; Jiang Qinghua. Research Progress on the Current Status and Countermeasures of Economic Toxicity Among Cancer Patients in China [J]. Nursing Research, 2022, 36(18):3299-3303.

[7] Zhan Mei; Wu Bin; Wu Fengbo; Xu Ting. Cost-effectiveness analysis of anlotinib in treating advanced non-small cell lung cancer [J]. Medical Herald, 2020, 39(2):172-175.

[8] Hu Yuhang; Yao Han; Liu Meicen; Liu Yuanli. Self-perceived Economic Burden of Inpatients in China's Tertiary Public Medical Institutions and Its Influencing Factors [J]. Medical and Social Sciences, 2024, 37(2):33-39.

[9] Yu Baorong, Feng Yingxue, Jiang Chenqing, Dai Xiang, Xu Haiyan, Wang Zhenhua. Economic Burden of Cancer and Health Insurance Policy Research [J]. Journal of Health Economics, 2018, 35(4):14-16.

[10] Tang Shidi; Zhi Hao; Zhu Cong; Wang Yongbo; Zeng Xiantao. Analysis of the Disease Burden of Testicular Cancer in China from 1990 to 2019 [J]. Journal of the PLA Medical Corps, 2024, 49(3):272-279.

[11] Dong Hui; Tang Zhiru; Yan Xun; Jiang Qicheng. Analysis of Malignant Tumor Treatment Costs in Anhui Province —— Based on the "Health Cost Accounting System 2011" [J]. Health Economics Research, 2021, 38(2):58-61.

[12] Zeng Yu; Liu Ying; Lü Jianxia; Jiang Hua; Mou Wenxuan; Jiang Luxi; Jiang Qinghua. Advances in Economic Toxicity Research for Gynecological Cancer Patients [J]. Nursing Research, 2023, 37(10):1783-1786.

[13] Zhou Ying. Factors Influencing Chemotherapy Compliance in Gynecological Cancer Patients: A Case-Control Study [J]. Practical Gynecological Endocrinology Electronic Journal, 2024, 11(16):26-28.

[14] Wang Lei; He Yong. Comprehensive Intervention Effects and Analysis of Antitumor Drugs in Use at a Hospital Under the Background of Medical Insurance Negotiations [J]. China Pharmaceutical, 2021, 30(14):15-19.

[15] Zhang Liyan; Shen Lin; Lu Yihan; Qin Yin. A Study on the Quality of Life and Related Factors Among 1,221 Cancer Survivors [J]. Electronic Journal of Comprehensive Cancer Treatment, 2020, 6(2):118-123.

[16] DAVIDOFF A J, ERTEN M, SHAFFER T, DAVIDOFF A J, ERTEN M, SHAFFER T, et al. Out-of-pocket health care expenditure burden for medicare beneficiaries with cancer [J]. Cancer, 2013, 119(6):1257-1265.

[17] BÜTTNER M, KÖNIG H H, LÖBNER M, et al. Out-of-pocketpayments and the financial burden of 502 cancer patients of working age in Germany: results from a longitudinal study [J]. Supportive Care in Cancer, 2019, 27(6):2221-2228.

[18] RAMSEY S, BLOUGH D, KIRCHHOFF A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis [J]. Health Affairs (Project Hope), 2013, 32(6):1143-1152.

[19] COLLADO L, BROWNELL I. The crippling financial toxicity of cancer in the United States [J]. Cancer Biology & Therapy, 2019, 20 (10):1301-1303.

[20] JÖNSSON B, HOFMARCHER T, LINDGREN P, et al. The cost and burden of cancer in the European Union 1995-2014 [J]. European Journal of Cancer, 2016, 66:162-170.